Jane Street
IMRX icon

Jane Street’s Immuneering IMRX Stock Holding History

Jane Street’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$118K Sell
22,300
-2,100
-9% -$10.8K ﹤0.01% 10548
2025
Q4 		$161K Buy
+24,400
New +$157K ﹤0.01% 9884

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jane Street's IMRX Position: Q1 2026 in Review

Jane Street reduced its Immuneering (IMRX) stake by 24% in Q1 2026, selling an estimated $126K and leaving 77,414 shares worth $408K. The position accounts for ﹤0.01% of the portfolio, ranked #8518.

Jane Street first reported a position in IMRX in Q1 2023 and has held it in 6 quarters since. The position peaked at $671K in Q4 2025. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

  • Jane Street held 77,414 shares of Immuneering worth $408K as of Q1 2026.
  • Jane Street sold 24,620 Immuneering shares in Q1 2026, an estimated $126K.
  • Immuneering made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #8518 holding.
  • Jane Street first reported a position in Immuneering in Q1 2023 and has held it in 6 quarters since.
  • Jane Street's Immuneering position peaked at $671K in Q4 2025.
  • 95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.